| Not Yet Recruiting | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) NCT07478991 | PETHEMA Foundation | Phase 3 |
| Recruiting | Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial) NCT06513273 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML NCT06652438 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 |
| Recruiting | Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/ NCT06532552 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients NCT06199557 | Haukeland University Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients NCT06252584 | University Hospital Tuebingen | Phase 1 |
| Unknown | Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult NCT06285136 | The Second Affiliated Hospital of Kunming Medical University | Phase 2 / Phase 3 |
| Withdrawn | Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Ma NCT06200441 | Ugur Arzu Kulu | — |
| Terminated | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemo NCT06449482 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Enrolling By Invitation | Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome NCT05674539 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 |
| Recruiting | Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With NCT05703126 | Samara State Medical University | N/A |
| Recruiting | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of NCT05601726 | Advanced BioDesign | Phase 1 / Phase 2 |
| Recruiting | A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagno NCT05133882 | Sunshine Lake Pharma Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia NCT05906914 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Active Not Recruiting | Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia NCT05001828 | Polaris Group | Phase 1 |
| Unknown | RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old. NCT05127798 | Grupo Argentino de Tratamiento de la Leucemia Aguda | — |
| Unknown | Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features NCT04752527 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Unknown | Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital St NCT04240600 | Hospital General de Mexico | N/A |
| Terminated | Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia NCT04425655 | University of California, San Diego | Phase 2 |
| Unknown | Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Inte NCT04454580 | Ospedale Maggiore Di Trieste | — |
| Completed | Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia NCT05988047 | University of Freiburg | — |
| Terminated | Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Trans NCT03951961 | University of Jena | Phase 2 |
| Recruiting | CLAG-GO for Patients With Persistent, Relapsed or Refractory AML NCT04050280 | University of Maryland, Baltimore | Phase 2 |
| Completed | Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75 NCT03902665 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 2 |
| Active Not Recruiting | Lentivirally Redirected CD123 Autologous T Cells in AML NCT03766126 | University of Pennsylvania | Phase 1 |
| Unknown | Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia NCT02985372 | Chunyan Ji | Phase 3 |